Dario Eklund, Santhera CEO
June 20, 2023 10:55 AM EDTUpdated 06:10 PM
Deals

Swiss biotech un­loads US rights to Duchenne can­di­date for $231M

Paul Schloesser

Associate Editor

San­thera, a Swiss biotech wait­ing to see if the FDA will ap­prove its steroid va­morolone for pa­tients with Duchenne mus­cu­lar dy­s­tro­phy in the fall, is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times